Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial

202316 citationsJournal Articlegold Open Access

Authors

Efficacy, safety, PK and immunogenicity were comparable between SB15 and AFL and between switched and non-switched participants.

Good health and well-being

Published in: BMJ Open Ophthalmology

Volume 8, Issue 1, pp. e001561-e001561

Field-Weighted Citation Impact: 4.43